eligibility_summary
Adults (≥18) with multiple myeloma who consent and are set to receive belantamab mafodotin per label (≥4 prior therapies, refractory to a PI, IMiD, and anti‑CD38, progression on last therapy), at hematologist’s discretion and able to cooperate with eye exams. Exclude if corneal disease, uncontrolled glaucoma, polyneuropathy, inability to comply with follow‑up, or hypersensitivity to belantamab/related drugs.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/intervention: Belantamab mafodotin (Belamaf) — an immunotherapy antibody–drug conjugate (IgG1 anti-BCMA) linked to monomethyl auristatin F (MMAF, a microtubule inhibitor). Mechanism: binds BCMA on malignant plasma cells, is internalized, and releases MMAF to inhibit tubulin polymerization and induce apoptosis, Fc effector functions (ADCC/ADCP) may contribute. Cells/pathways targeted: BCMA-expressing myeloma plasma cells, ocular off-target tissues under study include corneal epithelium, limbus/limbal stem cell region, and the subepithelial nerve plexus, assessing keratopathy and potential peripheral neurotoxicity via confocal microscopy. Observational, terminated due to FDA market withdrawal.